Binano Genomics Inc - About to take off 🚀 -Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Binano's Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research. Additionally, Binano's Saphyr appears to be more cost effective. The platform’s estimated cost of $500 per genome coming in far below the $10,000-20,000 per genome when HiFi and SMRT sequencing are put into action.
-Its one of our top stocks currently in our portfolio and today we would like to present you our opinions on this boy. Super positive news came previous weeks about Saphyr. Social sentiment on this stock gets more and more positive every day. It started catching good daily volumes. We can see a Bullish Pennant on this chart. We feel very bullish on this one. We wish safe trades to everybody!
